NCT07758634RecruitingPhase 1/2
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension
A Phase 1/2 Multicenter, First-in-human, Ascending Dose Trial Evaluating the Safety, Tolerability, and Efficacy of a Lipid Nanoparticle Formulation of CRISPR-Guide RNA-Cas9 Nuclease (CTX340) for In Vivo Editing of the Angiotensinogen (AGT) Gene in Participants With Hypertension
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
A Study of CTX340 in Participants with Uncontrolled Hypertension.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 69 (estimated)
- First submitted
- 6 Aug 2026
- Start date
- 8 Aug 2026
- Primary completion date
- 1 Jul 2028
- Lead sponsor
- CRISPR Therapeutics AG
- Diseases
- High blood pressure
- NCT number
- NCT07758634
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 69
- From 8 Aug 2026 to the primary completion date, 1 Jul 2028
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants with vascular cause of hypertension which may be amendable to revascularization
- Participants with treatable/reversible causes of uncontrolled hypertension
- History of renal artery denervation within past 12 months.
- Evidence of liver disease
- History of a significant coagulation disorder.
- Uncontrolled or untreated thyroid disease
Lab values
- Serum aldosterone and direct renin concentration (or plasma renin activity \[PRA\]) suggestive of primary aldosteronism
- Complete blood count (CBC) outside the specified ranges per protocol.
Other
- Mean diastolic blood pressure (DBP) ≤65 mm Hg on screening ABPM.
- Orthostatic hypotension
Who the study is looking for
- Age: ≥18 and ≤75 years.
- Body mass index ≤40 kg/m2.
- 24-hour mean ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP) measurement of ≥130 mm Hg but ≤160 mm Hg despite treatment
- Be on treatment with ≥4 antihypertensive therapies at effective doses, of which ≥1 must be a diuretic.
- Participants who at any point had childbearing potential must currently be postmenopausal
- All participants capable of producing sperm must agree to the use of an acceptable method of effective contraception and their partners with childbearing potential should also agree to use an effective method of contraception.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Melbourne | Australia | Recruiting |
| - Coordinator of this site? Confirm its status | Port Orange | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.